MiMedx Group, Inc.MDXGNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank95
5Y CAGR+73.2%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+73.2%/yr
Long-term compound
Percentile
P95
Near historical high
vs 5Y Ago
15.6x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 28.63% |
| Q3 2025 | 12.11% |
| Q2 2025 | -0.75% |
| Q1 2025 | -6.80% |
| Q4 2024 | 22.38% |
| Q3 2024 | -3.12% |
| Q2 2024 | 6.02% |
| Q1 2024 | 16.77% |
| Q4 2023 | -20.88% |
| Q3 2023 | -16.26% |
| Q2 2023 | 5.40% |
| Q1 2023 | -35.48% |
| Q4 2022 | -9.29% |
| Q3 2022 | 8.00% |
| Q2 2022 | -7.58% |
| Q1 2022 | 30.39% |
| Q4 2021 | 4.72% |
| Q3 2021 | 7.51% |
| Q2 2021 | -6.36% |
| Q1 2021 | 26.35% |
| Q4 2020 | 1.84% |
| Q3 2020 | 49.27% |
| Q2 2020 | -14.75% |
| Q1 2020 | -2.54% |
| Q4 2019 | 1.04% |
| Q3 2019 | -4.84% |
| Q2 2019 | -2.55% |
| Q1 2019 | -36.08% |
| Q4 2018 | 14.59% |
| Q3 2018 | 6.53% |
| Q2 2018 | 4.91% |
| Q1 2018 | 2.16% |
| Q4 2017 | -36.69% |
| Q3 2017 | 15.46% |
| Q2 2017 | 12.97% |
| Q1 2017 | 21.59% |
| Q4 2016 | 18.40% |
| Q3 2016 | -7.86% |
| Q2 2016 | 26.92% |
| Q1 2016 | 6.62% |